Meeting
Abstract Number: 113
SHM Converge 2023
Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects at least 20% of the general population. There is a significant predominance of IBS in females, with a female: male ratio of 2:1, especially in western countries. In contrary Eastern countries, some studies report that men with IBS are 4 times more affected […]
Abstract Number: 125
SHM Converge 2023
Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being […]
Abstract Number: 127
SHM Converge 2023
Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a […]
Abstract Number: 280
SHM Converge 2023
Background: Racial minorities are underrepresented in cancer-related clinical trials. One commonly recognized contributor to this is medical mistrust. Methods: This study used data from the 2020 National Cancer Institute’s Health Information National Trends Survey (HINTS), a cross-sectional, nationally representative sample of 3865 participants. We sought to determine the prevalence of medical mistrust and its impact […]